IL264956A - Anti-pd1 monoclonal antibody, pharmaceutical preparation thereof and use thereof - Google Patents
Anti-pd1 monoclonal antibody, pharmaceutical preparation thereof and use thereofInfo
- Publication number
- IL264956A IL264956A IL264956A IL26495619A IL264956A IL 264956 A IL264956 A IL 264956A IL 264956 A IL264956 A IL 264956A IL 26495619 A IL26495619 A IL 26495619A IL 264956 A IL264956 A IL 264956A
- Authority
- IL
- Israel
- Prior art keywords
- monoclonal antibody
- antibody
- seq
- antigen
- binding fragment
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 230000027455 binding Effects 0.000 claims description 97
- 239000000427 antigen Substances 0.000 claims description 84
- 108091007433 antigens Proteins 0.000 claims description 84
- 102000036639 antigens Human genes 0.000 claims description 84
- 239000012634 fragment Substances 0.000 claims description 66
- 210000004027 cell Anatomy 0.000 claims description 52
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 27
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims description 25
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 25
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 24
- 210000004408 hybridoma Anatomy 0.000 claims description 22
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 21
- 108010002350 Interleukin-2 Proteins 0.000 claims description 20
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 12
- 239000003446 ligand Substances 0.000 claims description 12
- 230000014509 gene expression Effects 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 201000001441 melanoma Diseases 0.000 claims description 9
- 208000007502 anemia Diseases 0.000 claims description 8
- 238000004113 cell culture Methods 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 claims description 7
- 206010062016 Immunosuppression Diseases 0.000 claims description 7
- 206010033128 Ovarian cancer Diseases 0.000 claims description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 7
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 7
- 230000001506 immunosuppresive effect Effects 0.000 claims description 7
- 208000032839 leukemia Diseases 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 206010038389 Renal cancer Diseases 0.000 claims description 5
- 230000001268 conjugating effect Effects 0.000 claims description 5
- 201000010982 kidney cancer Diseases 0.000 claims description 5
- 239000003550 marker Substances 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 238000003745 diagnosis Methods 0.000 claims description 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 230000002285 radioactive effect Effects 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 230000000903 blocking effect Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 230000002222 downregulating effect Effects 0.000 claims description 2
- 230000004001 molecular interaction Effects 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 82
- 102000000588 Interleukin-2 Human genes 0.000 description 18
- 239000013598 vector Substances 0.000 description 15
- 230000028327 secretion Effects 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 238000002965 ELISA Methods 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 11
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 7
- 229960003301 nivolumab Drugs 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 241000283707 Capra Species 0.000 description 5
- 101710160107 Outer membrane protein A Proteins 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000010494 dissociation reaction Methods 0.000 description 5
- 230000005593 dissociations Effects 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 238000009098 adjuvant therapy Methods 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000004088 simulation Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 101000840257 Homo sapiens Immunoglobulin kappa constant Proteins 0.000 description 2
- 101710138871 Ig gamma-1 chain C region Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 102100039345 Immunoglobulin heavy constant gamma 1 Human genes 0.000 description 2
- 102100029572 Immunoglobulin kappa constant Human genes 0.000 description 2
- 239000012515 MabSelect SuRe Substances 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
- 210000004507 artificial chromosome Anatomy 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 239000012997 ficoll-paque Substances 0.000 description 2
- 238000000703 high-speed centrifugation Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000009874 shenqi Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101150100936 CD28 gene Proteins 0.000 description 1
- 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 102000014447 Complement C1q Human genes 0.000 description 1
- 108010078043 Complement C1q Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 108010076818 TEV protease Proteins 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000014107 chromosome localization Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 102000048362 human PDCD1 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229940125645 monoclonal antibody drug Drugs 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 230000007896 negative regulation of T cell activation Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70521—CD28, CD152
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7019—Ischaemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
and Use Thereof Technical Field The present invention belongs to the field of tumor therapy and molecular immunology, relating to an anti-PD1 antibody, the pharmaceutical composition and methods of use.
Specifically, the present invention relates to an anti-PD1 monoclonal antibody.
Technical Background The transmembrane receptor PD1 (programmed cell death 1, also known as PD-1) is a member of the CD28 gene family, expressed in activated T cells, B cells and myeloid cells.
Both ligands of PD1 (i.e. PDL1 and PDL2) belong to the B7 superfamily; wherein PDL1 is broadly expressed in a variety of cells including T cells, B cells, endothelial cells and epithelial cells, while PDL2 is only expressed in antigen presenting cells such as dendritic cells and macrophages.
T cells play a very important role in the elimination of viral infections, and T cell antiviral response is usually associated with immunopathogenesis. PD1 plays a vital role in the negative regulation of T cell activation. Although PD1-mediated negative regulation on T cells can reduce tissue damage caused by infection, blocking or inhibiting the negative regulatory effect of PD1 may lead to autoimmune diseases, for example, pancreatic virus infection can be more effectively eliminated in PD1 gene knockout mice, but may lead to more severe liver damage (Isai et al., 2003, J.Exp.Med.198:39-50). In addition, tumors with highly expressed PD1 often develop into cancers that are difficult to detect (Hamanishi et al., 2007, Proc.Natl.Acad.Sci.USA 104:3360-5). An established method to regulate PD1 expression is through injection of antibodies into the body.
Due to the broad antitumor prospects and astounding efficacy of PD1 antibody, it is 1 199462198 v1 treatment of a variety of tumors: non-small cell lung cancer, renal cell carcinoma, ovarian cancer, melanoma (Homet M.B., Parisi G., et al., Anti-PD1 Therapy in Melanoma. Semin Oncol. 2015 Jun;42(3):466-473), leukemia, and anemia (Held SA, Heine A, et al., Advances in immunotherapy of chronic myeloid leukemia CML. Curr Cancer Drug Targets. 2013 Sep;13(7):768-74).
Ever since the revelation of the unprecedented clinical efficacy data at the annual meetings of American Association for Cancer Research (AACR) and American Society of Clinical Oncology (ASCO) in 2012 and 2013, PD1 antibodies have become the hottest new drugs in R&D in the global pharmaceutical industry.
At present, there is still a need to develop new anti-PD1 antibodies with better binding efficiency to effectively block the binding of PD1 to PDL1.
Summary of the Invention Through in-depth research and creative work, by immunizing mice with recombinant PD1 expressed in mammalian cells expression system as antigen, the inventors obtained hybridoma cells via fusion of mouse splenocytes and myeloma cells. By screening a large number of samples, the inventors obtained the hybridoma cell line LT003 (CCTCC Deposit Accession No.: C2015105).
The inventors surprisingly found that the hybridoma cell line LT003 is capable of secreting a specific monoclonal antibody (named 14C12) binding specifically to PD1, and this monoclonal antibody can effectively block the association of PD1 to PDL1.
Furthermore, the inventors generated a humanized anti-PD1 antibody (named 14C12H1L1) in a creative way.
More surprisingly, the inventors found that the antibodies 14C12 and 14C12H1L1 herein can effectively bind to human T cells, activate T cells and induce the secretion of IFN-y and 2 199462198 v1 potential to become drugs for preventing and treating malignancies including lung cancer, melanoma, renal cancer, ovarian cancer and leukemia, as well as anemia.
The following are provided by the present invention: The present invention relates to a monoclonal antibody or its antigen-binding fragments thereof, wherein, the heavy chain variable region (Vh) of the said monoclonal antibody comprises: CDRs with the amino acid sequences of SEQ ID NO:9-11; and/or the light chain variable region (Vl) of the said monoclonal antibody comprises: CDRs with the amino acid sequences of SEQ ID NO:12-14.
In some examples of the present invention, the said monoclonal antibody or its antigen-binding fragments thereof, wherein, the amino acid sequence of Vh of the monoclonal antibody is chosen from SEQ ID NO:2 and SEQ ID NO:6; and/or the amino acid sequence of Vl of the monoclonal antibody is chosen from SEQ ID NO:4 and SEQ ID NO:8.
In an example of the present invention, the said monoclonal antibody or its antigen-binding fragments thereof, wherein, the monoclonal antibody comprises: (1) Vh shown by SEQ ID NO:2 and Vl shown by SEQ ID NO:4; (2) Vh shown by SEQ ID NO:6 and VL shown by SEQ ID NO:8.
The variable regions in heavy and light chains of an antibody govern binding activity.
Each chain contains three hypervariable regions, namely, the complementary determining region (CDR) (HCDR1, HCDR2 and HCDR3 in heavy (H) chain, and LCDR1, LCDR2 and 3 199462198 vl Immunological Interest, Fifth Edition (1991), volume 1-3, NIH Publication 91-3242, Bethesda MD).
Through techniques well-known to technical personnel in the field described herein, for example, analyzing the amino acid sequences in the CDR of the monoclonal antibody sequences in Items (1) and (2) above through VBASE2 database: The antibodies 14C12 and 14C12H1L1 herein comprises the same CDR: Wherein the amino acid sequences of the 3 CDR regions of Vh are as follows: HCDR1: GFAFSSYD (SEQ ID NO:9), HCDR2: ISGGGRYT (SEQ ID NO:10), HCDR3: ANRYGEAWFAY (SEQ ID NO:11); Wherein the amino acid sequences of the 3 CDR regions of Vl are as follows: LCDR1: QDINTY (SEQ ID NO:12), LCDR2: RAN (SEQ ID NO:13), LCDR3: LQYDEFPLT (SEQ ID NO:14).
In certain example, the said monoclonal antibody or its antigen-binding fragment thereof, wherein the said monoclonal antibody or its antigen-binding fragment are selected from Fab, Fab’, F(ab’)2, Fd, Fv, dAb, CDRs, single chain antibodies (e.g. scFv), humanized antibodies, chimeric antibodies, or bispecific antibodies.
In certain embodiments, the said monoclonal antibody or its antigen-binding fragment thereof, wherein the said monoclonal antibody binds to PD1 protein with Kd less than approximately 105־ M, for example, less than approximately 106־ M, 107־ M, 108־ M, 109־ M, 1010־ M, or less; preferably, detected by Fortebio molecular interaction equipment.
In certain embodiments, the said monoclonal antibody or its antigen-binding fragment thereof, wherein the said monoclonal antibody binds to PD1 protein with EC50 less than 4 199462198 vl 0.5 nM, 0.4 nM, 0.3 nM, 0.2 nM, 0.1 nM or less. Specifically, the said EC50 is determined by an indirect ELISA.
In certain embodiments, the said monoclonal antibody or its antigen-binding fragment thereof, wherein the said monoclonal antibody binds to PD1 protein with Kd less than approximately 10-5 M, such as less than approximately 10-6 M, 10-7 M, 10-8 M, 10-9 M, 10-10 M, or less, In certain embodiments, the said monoclonal antibody or its antigen-binding fragment thereof, wherein the said monoclonal antibody contains non-CDR regions from species other than mouse, for example, from human.
In certain embodiments, the said monoclonal antibody or its antigen-binding fragments thereof, wherein the said monoclonal antibody is produced by the hybridoma cell line LT003, and the said hybridoma cell line LT003 is preserved in China Center for Type Culture Collection (CCTCC) with the CCTCC Deposit Accession NO: C2015105.
The present invention relates to an isolated nucleic acid molecule comprising a nucleotide sequence capable of encoding Vh of the antibody, wherein, the Vh of the said antibody comprises: CDRs with the amino acid sequences from SEQ ID NO:9-11; Specifically, the heavy chain of the said antibody has the amino acid sequences from SEQ ID NO:2 and SEQ ID NO:6; More specifically, the said nucleic acid molecule has the nucleotide sequences from SEQ ID NO: 1 or SEQ ID NO:5.
The present invention relates to an isolated nucleic acid molecule comprising a nucleotide sequence capable of encoding Vl of the antibody, wherein, 199462198 vl NO:12-14; Specifically, the Vl of the said antibody has the amino acid sequences from SEQ ID NO:4 or SEQ ID NO: 8; More specifically, the said nucleic acid molecule has the nucleotide sequences from SEQ ID NO:3 or SEQ ID NO:7.
The present invention relates to a vector comprising the isolated nucleic acid molecule described in the present invention.
The present invention relates to a host cell comprising the isolated nucleic acid molecule described in the present invention, or vector described in the present invention.
The present invention relates to a method for preparing the monoclonal antibody or its antigen-binding fragments thereof described in the present invention, by culturing the host cell in the present invention under appropriate conditions, and recovering the said monoclonal antibody or its antigen-binding fragments thereof from the cell culture.
The present invention relates to the hybridoma cell line LT003 that is preserved in the China Center for Typical Culture Collection (CCTCC) with the CCTCC Deposit Accession NO: C2015105.
The present invention relates to a conjugate that consist of monoclonal antibody or its antigen binding fragments and conjugating part, wherein, the said monoclonal antibody is monoclonal antibody or its antigen binding fragments described in the present invention, and the said conjugating part as a detectable marker. Specifically, the said conjugating part are radioactive isotopes, fluorescein, luminescent materials, colorful substances, or enzymes. 6 199462198 vl antigen binding fragments, or the conjugates thereof described in the invention; Specifically, the reagent kits may contain a secondary antibody, which specifically recognizes the said monoclonal antibody or its antigen binding fragments; optionally, the said secondary antibody may contain detectable markers, such as radioactive isotopes, fluorescein, luminescent materials, colorful substances, or enzymes.
The present invention relates to use of the said monoclonal antibody or its antigen binding fragments, or the conjugates thereof described in the invention in preparation of reagent kits, the said reagent kits are used in detection of the existence or the level of PD1 in samples.
The present invention relates to a pharmaceutical composition comprising the said monoclonal antibody or its antigen binding fragments, or the conjugates thereof described in the invention. Optionally, it may also comprise a pharmaceutically acceptable carrier or excipient.
The present invention relates to use of the said monoclonal antibody or its antigen binding fragments or the conjugates thereof described in the invention in preparing drugs for prevention and/or treatment and/or adjuvant treatment and/or diagnosis of tumors or anemia; specifically, the said tumors may be melanoma, renal cancer, prostate cancer, bladder cancer, colorectal cancer, gastrointestinal cancer, liver cancer, non-small cell lung cancer, ovarian cancer and leukemia.
The present inventors have found through animal experiments that, 14C12H1L1 can effectively inhibit the growth of MC38 tumor cells inoculated at right side subcutaneously in PD-1 HuGEMM mice, which the antibody drug 14C12H1L1 can significantly inhibit the tumor growth in PD-1 HuGEMM tumor-bearing mice, having an efficacy equivalent to the marketed monoclonal antibody drug Nivolumab that is approved drug targeting the same target.
The present invention relates to use of the monoclonal antibody or its antigen-binding fragments or the conjugates thereof described in the present invention for preparation drugs 7 199462198 v1 Blocking the binding of PD1 to PD1 ligand, Regulating (e.g. Down-regulating) PD1 activity or level, Relieving the immunosuppression of PD1, or Up-regulating IFN-y and/or IL-2 expressions in T lymphocytes; Specifically, the said PD1 ligand is PDL1 or PDL2, preferably PDL1.
The present invention relates to an in vivo or in vitro method to apply to cells or subjects in need with an effective dose of the monoclonal antibody or its antigen-binding fragments or the conjugates thereof described in the present invention, and the said method is selected from the following: Methods to block the binding of PD1 to PD1 ligand, Methods to regulate (e.g. down-regulate) PD1 activity or level, Methods to relieve the immunosuppression of PD1, or Methods to up-regulate IFN-y and/or IL-2 expressions in T lymphocytes; Specifically, the said PD1 ligand is PDL1 or PDL2, preferably PDL1.
In a specific example of the present invention, the said in vitro method is intended for non-therapeutic or -diagnostic purposes.
Interferon y (IFNy), is mainly naturally produced by natural killer (NK) cells and natural killer T (NKT) cells, or produced by effector T cells consisting of CD4 Th1 cells and CD8 cytotoxic T lymphocytes after being stimulated by specific antigens. As an important cytokine of innate and acquired immune, IFNy plays an import role in antagonizing or inhibiting viral, some bacterial and protozoon infections. In the meantime, IFNy can activate macrophages and induce the expression of type 2 major histocompatibility complex (MHC) to activate immune responses to control the progression of tumors (Schoenborn JR, Wilson CB. Regulation of 8 199462198 v1 96:41-101). In the in vitro study of the present invention, the anti-PD1 antibody can induce the secretion of IFNy to activate immune responses.
Interleukin 2 (IL-2) produced by T cells is a growth factor regulating T cell subsets and a crucial factor regulating immune responses, promoting activated B cells proliferation, and participating in antibody responses, hematopoiesis and oncological surveillance. Recombinant human IL-2 has been approved by the U. S. FDA for the treatment of malignant tumors (including melanoma, renal tumor, etc.) while undergoing clinical studies for the treatment of chronic viral infections (Chavez, A.R., et al., Pharmacologic administration of interleukin-2.
Ann N Y Acad Sci, 2009.1182:p.14-27). In vitro studies, the anti-PD1 antibody of the present invention can specifically relieve the immunosuppression of PD1, activate T cells and induce IL-2 production, displaying promising prospects of extensive applications in gene therapies for neoplastic and parasitic diseases.
The monoclonal antibody or its antigen-binding fragments or the conjugates thereof described in the present invention is used for the prevention and/or treatment and/or adjuvant treatment and/or diagnosis of tumors or anemia; specifically, the said tumors may be melanoma, renal cancer, prostate cancer, bladder cancer, colorectal cancer, gastrointestinal cancer, liver cancer, non-small cell lung cancer, ovarian cancer or leukemia.
The monoclonal antibody or its antigen-binding fragments or the conjugates thereof described in the present invention is used to: Block the binding of PD1 to PD1 ligand, Regulate (e.g. down-regulate) PD1 activity or level, Relieve the immunosuppression of PD1, or Up-regulate IFN-y and/or IL-2 expressions in T lymphocytes; Specifically, the said PD1 ligand is PDL1 or PDL2, preferably PDL1. 9 199462198 v1 antigen-binding fragments or the conjugates thereof described in the present invention only blocks the binding of PD1 to PDL1.
The present invention relates to a method for the prevention and/or treatment and/or adjuvant treatment and/or diagnosis of tumors or anemia, including the procedure to apply to subjects with an effective dose of the monoclonal antibody or its antigen-binding fragments or the conjugates thereof described in the present invention; specifically, the said tumors may be melanoma, renal cancer, prostate cancer, bladder cancer, colorectal cancer, gastrointestinal cancer, liver cancer, non-small cell lung cancer, ovarian cancer or leukemia.
Unless otherwise defined herein, scientific and technical terms used in connection with the present invention shall have the meanings that are commonly understood by those of ordinary skill in the art. Furthermore, laboratory techniques of cell and tissue culture, molecular genetics, oligo- or polynucleotide chemistry, and immunology described herein are those well-known and commonly used in the art. Meanwhile, to better understand the present invention, the following terms, unless otherwise indicated, shall be understood to have the following meanings: As used in this invention, the term "Amino acid sequence of PD1 protein (Programmed cell death protein 1, NCBI GenBank: NP_005009.2)" comprises the full length PD1 protein, or PD1ECD (extracellular segment of PD1) or PD1ECD-containing fragments; and also comprises the fusion protein of PD1ECD, for example, fused with the Fc protein fragments of mouse or human IgG (mFc or hFc). Furthermore, understood by those of ordinary skill in the art, the amino acid sequence of PD1 protein can have naturally or artificial mutations (including but not limited to substitutions, deletions, and/or additions), not affecting its biological functions. Therefore, in the present invention, the term "PD1 protein" should include 199462198 v1 sequence fragments of PD1 protein, the said sequence fragments comprise both the sequence fragments and the corresponding sequence fragments in its natural or artificial variants.
As used in this invention, the term "Amino acid sequence of PDL1 protein (Programmed death-ligand 1, NCBI Genebank ID: NP_054862.1)" comprises the full length PDL1 protein, or PDL1ECD (extracellular segment of PDL1) or PDL1ECD-containing fragments; and also comprises the fusion protein of PDL1ECD, for example, fused with the Fc protein fragments of mouse or human IgG (mFc or hFc). Furthermore, understood by those of ordinary skill in the art, the amino acid sequence of PDL1 protein can have naturally or artificial mutations (including but not limited to substitutions, deletions, and/or additions), not affecting its biological functions. Therefore, in the present invention, the term "PDL1 protein" should include all such sequences and their natural or artificial variants. Furthermore, when describing the sequence fragments of PDL1 protein, the said sequence fragments comprise both the sequence fragments and the corresponding sequence fragments in its natural or artificial variants.
As used in this invention, the term "EC50" refers to the concentration for 50% of maximal effect.
As used in this invention, the term "antibody" refers to immunoglobulin proteins, which typically composed of two pairs of polypeptide chains (each pair has a "light" (L) chain and a "heavy" (H) chain). The light chains are classified as k and X light chains. The heavy chains are classified as 5 ,!ן, y, a, or 8, and respectively, define isotype antibodies as IgM, IgD, IgG, IgA and IgE. In light chains and heavy chains, variable regions and constant regions are connected by a "J" region consisting of about 12 or more amino acids. The heavy chain also contains a "D" region with about 3 or more amino acids. Each heavy chain contains a variable region (Vh) and a constant region (Ch), which consists of 3 domains (Ch1, Ch2, and Ch3). 11 199462198 v1 one domain Cl. The constant region can mediate the binding of immune globulin to host tissues or factors, including various cells in the immune system (e.g., effector cells) and the complement component 1q (C1q) of the classical complement system. Vh and Vl can also be subdivided into regions with high variability (called complementarity determining region (CDR)), which are separated by relatively conservative regions called framework regions (FR).
From the amino terminus to the carboxyl terminus, each Vh and Vl is composed of 3 CDRs and 4 FRs, in the order of FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The variable regions (Vh and Vl) of the heavy chain and light chain form the antibody binding site.
Distribution of amino acids to the regions or domains follow the definitions by Kabat in Sequences of Proteins of Immunological Interest (National Institutes of Health Bethesda, MD (1987 and 1991)), or Chothia & Lesk (1987) Mol. Biol., 196:901-917; or Chothia et al. (1989) Nature, 342:878-883. The term "antibody" is not restricted by any particular method of producing them. For example, it includes, in particular, recombinant antibodies, monoclonal antibodies, and polyclonal antibodies. Antibodies can be different isotypes, for example, IgG (such as IgG1, IgG2, IgG3, or IgG4 subtype), IgA1, IgA2, IgD, IgE, or IgM antibodies.
As used in this invention, the term "antigen binding fragments" refers to a polypeptide containing fragments of a full-length antibody, maintaining the ability to bind specifically to the same antigen, and/or to compete with the full length antibody to bind to the antigen, which is also called "the antigen binding portion". See Fundamental Immunology, Ch. 7 (Paul, W., ed. 2, Raven Press, N. Y. (1989)), including the entire article and references in this invention for all purposes. Antigen binding fragments can be generated by recombinant DNA techniques or by cleaving intact antibodies with proteolytic enzymes or chemicals. In some cases, the antigen binding fragments include Fab, Fab’, F(ab')2, Fd, Fv, dAb, and CDR fragments, single chain antibodies (e.g., scFv), chimeric antibodies, diabody, and the polypeptides that at least contains an antibody portion which is sufficient to confer a specific antigen binding capacity to the 12 199462198 vl In some cases, the antigen binding fragment is a diabody, namely, a dimeric antibody fragment, whose Vh and Vl domains are expressed on a single polypeptide chain, however, because of using a too short linker the to allow pairing between the two domains of the same chain, the domains are forced to pair with complementary domains on another chain to generate two antigen binding sites (see, for example, Holliger P. et al., Proc. Natl. Acad. Sci.
USA 90: 6444-6448 (1993), and Poljak R. J. et al., Structure 2: 1121-1123 (1994)).
Using conventional techniques known by those of ordinary skill in the art (such as recombinant DNA technology or enzymatic/chemical cleavage), an antigen binding fragment (such as the above described antibody fragments) may be obtained from a given antibody (e.g. monoclonal antibodies 14C12, 14C12H1L1 provided herein in the invention), and screened for specificity in the same manner as for the full antibody.
In this invention, unless specified otherwise, the term "antibody" refers to not only the intact antibody, but also the antigen binding fragments of the antibody.
As used in this invention, the terms "mAb" and "monoclonal antibodies" refers to an antibody or a fragment of an antibody that is derived from a group of highly homologous antibodies, i.e. from a group of identical antibody molecules, except for mutations that may arise spontaneously. Monoclonal antibody has high specificity against a single epitope on the antigen. Polyclonal antibodies are different from monoclonal antibodies, containing at least 2 or more different antibodies, which usually recognize different epitopes on the antigen.
Monoclonal antibodies can be obtained with hybridoma technology reported originally by Kohler et al., (Nature, 256: 495, (1975)), as well as recombinant DNA Technology (see U.S.
Patent 4,816,567).
As used in this invention, the term "humanized antibody" refers to an antibody or its fragments, derived from a human immunoglobulin (receptor antibody), whose CDRs or part of CDRs are replaced by the CDR regions of a non-human antibody (donor antibody), where the 13 199462198 vl predictive specificity, binding affinity, or reactivity. In addition, some amino acid residues of the receptor antibody framework region (FR) can also be replaced by the corresponding amino acid residues of the non-human source, or replaced by the amino acid residues of other antibodies to further improve or optimize the performance of the antibody. For more details on humanized antibodies, see for example Jones, et al., Nature, 321: 522-525 (1986); Reichmann et al., Nature, 332: 323-329 (1988); Presta, Curr. Op. Struct. Biol., 2: 593-596 (1992); and Clark, Immunol. Today, 21: 397-402 (2000).
As used in this invention, the term "isolate" or "isolated" means obtained by artificial means in the natural state. If there is a certain kind of "isolated" matter or component in nature, it may be due to the change in its natural environment, or isolated from the natural environment, or both. For example, polynucleotide or polypeptide in a natural existence in a living animal will be called "isolated" if it was separated with high purity in the same natural state. The term "isolate" or "isolated" does not exclude existence of artificial or synthetic material, or other impurities that does not affect the activity.
As used in this invention, the term "vector" refers to a nucleic acid delivery vehicle that can be inserted with polynucleotide. The vector that can have the protein that is encoded by the inserted polynucleotide expressed is called an expression vector. Vectors can be inserted into the host cell by transformation, transduction, or transfection, so the genetic substances carried by the vector can be expressed in the host cell. Vectors are well known to the technical personnel in the field, including but not limited to: plasmid; phasmid; cosmid; artificial chromosome such as yeast artificial chromosome (YAC), bacterial artificial chromosome (BAC), or P1 derived artificial chromosome (PAC); phage such as X phage or M13 phage and animal viruses etc. Animal viruses may include but not limited to, reverse transcriptase virus (including lentivirus), adenovirus, adeno-associated virus, herpes virus (e. g. herpes simplex virus), chicken pox virus, baculovirus, papilloma virus, and papova virus (such as SV40). A 14 199462198 v1 promoter, transcription initiation factor, enhancer, selection element, and reporter gene. In addition, the vector may also contain replication initiation site.
As used in this invention, the term "host cell" refers to cells that can import vectors, including but not limited to, prokaryotic cells such as E. coli and Bacillus subtilis, fungal cells such as yeast and Aspergillus, insect cells such as S2 drosophila cells and Sf9, or animal cells such as fibroblast cells, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK293 cells or human cells.
As used in this invention, the term "specific binding" refers to a non-random binding between two molecules, such as the interaction between the antibody and its target antigen. In some embodiments, a specific binding of an antibody to an antigen means an affinity (Kd), for example less than about 10-5 M, in particular, less than 10-6 M, 10-7 M, 10-8 M, 10-9 M, 10-10 M, or less.
As used in this invention, the term "Kd" refers to the dissociation equilibrium constant of specific interaction between antibody and antigen, to describe the binding affinity between antibodies and antigens. The smaller the equilibrium dissociation constant is, the tighter the antibody binds antigen, the higher the affinity between the antibody and the antigen is.
Typically, antibodies (e.g., monoclonal antibodies 14C12, 14C12H1L1 in the present invention) bind to antigens (e.g., PD1 protein) with a Kd less than approximately 10-5 M, for example, less than 10"6 M, 10"7 M, 10"8 M, 10"9 M or 10"10 M or even less. Kd can be measured by any method well known to the technical personnel in the field, for example, using Fortebio Octet System As used in this invention, the terms "monoclonal antibody" and "mAb" have the same meaning and are used interchangeably; the terms "polyclonal antibody" and "PcAb" have the same meaning and are used interchangeably; the terms "polypeptide" and "protein" have the same meaning and are used interchangeably. Also in the present invention, amino acids are usually represented by single letter or three letter abbreviations known to this field. For 199462198 v1 As used in this invention, the terms "hybridoma" and "hybridoma cell line" can be used interchangeably, and when mentioned herein, include the subclone and progeny cells of hybridoma. For example, when mentioned herein, hybridoma cell line LT003 also includes the subclone and progeny cells of LT003.
As used in this invention, the term "pharmaceutically acceptable carrier or excipient" refers to a carrier and/or an excipient pharmaceutically and/or physiologically compatible with subjects and active ingredients, and widely recognized in the field herein (Remington’s Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995), including but not limited to: pH adjustors, surfactants, adjuvants, and ionic strength enhancers. For example, pH adjustors include but not limited to phosphate buffer solution; surfactants include but not limited to cationic, anionic or nonionic surfactants such as Tween-80; ionic strength enhancers include but not limited to sodium chloride.
As used in this invention, the term "effective dose" is defined as an amount of a therapeutic sufficient to achieve or at least partially achieve the desired effect. For example, effective prevention dose (e.g. for cancer) is the amount to prevent, stop, or delay the occurrence of diseases (e.g. cancer); effective treatment dose is the amount to cure, or at least partially stop, the disease and its complications in patients with the disease. Determination of such an effective dose is entirely within the scope of the capabilities of the technical personnel in the field. For example, the effective treatment dose will depend on the severity of the disease, the overall state of the patient's immune system, the general background of patients such as age, weight and gender, administration method of the said drug, and other concomitant treatments, etc.
Effects of the Invention The monoclonal antibodies in the present invention, especially 14C12H1L1, is capable of 16 199462198 v1 the immunosuppression of PD1 to activate T lymphocytes. Wherein, the PD1 antibody 14C12H1L1 can induce the secretions of IFN-y and IL-2 much better than the control antibody 5C4 (5C4: PD1 antibody from Medarex Inc.: Alan J.Korman, et al., Human monoclonal antibodies to programmed death 1 (PD1) and methods for treating cancer using anti-PDl antibodies alone or in combination with other immunotherapeutics, United States Patent, Patent No.US 8008449 B2). The monoclonal antibodies of the present invention, especially 14C12H1L1, have an antitumor effect equivalent to the approved drug Nivolumab for the same target. The antibodies of the present invention have the potential to become or to be prepared into drugs for the prevention and/or treatment of non-small cell lung cancer, renal cell carcinoma, ovarian cancer, melanoma, leukemia or anemia.
Description of Figures Figure 1: SDS-PAGE Results of Humanized Monoclonal Antibody 14C12H1L1. From left to right: 1. 1 |!g antibody in non-reduced loading buffer; 2. 1 |!g antibody in reduced loading buffer; 5 p,L Marker; 3. 1 p,g BSA.
Figure 2: Binding kinetics of Antibody 14C12.
Figure 3: Binding kinetics of Antibody 14C12H1L1.
Figure 4: Binding kinetics of Antibody 5C4.
Figure 5: ELISA results of 14C12H1L1 and 5C4 binding to PD1.
Figure 6: Competition ELISA results of 14C12H1L1 and 5C4 binding to PD1 against PDL1.
Figure 7: EC50 of 14C12H1L1 binding to PD1 on the Surface of 293T-PD1 Cells.
Figure 8: Binding activity of 14C12H1L1 to T Cell Surface Antigen PD1.
Figure 9: Effect of 14C12H1L1 on IFN-y Secretion of Mixed Lymphocytes.
Figure 10: Effect of 14C12H1L1 on IL-2 Secretion of Mixed Lymphocytes. 17 199462198 v1 PBMC, MDA-MB-231 and Raji Cells.
Figure 12: Effect of 14C12H1L1 on the Tumor Growth of MC38 Tumor Model in PD-1 HuGEMM Mice.
Hybridoma cell line LT003, has been preserved in the China Center for Typical Culture Collection (CCTCC) in Wuhan University, Wuhan, China 430072 on June 16, 2015 with CCTCC Deposit Accession NO: C2015105 Detailed description of the invention The invention will now be described in detail. As will be appreciated by one skilled in the art, the following examples are only used for the description of the invention, and not to be deemed to limit the scope of the invention. The cases without the specific descriptions of techniques or conditions were carried out in accordance with the literature in the field (e.g., Guide to Molecular Cloning, written by J Sambrook, et al, translated by Peitang Huang, et al, third Edition, Science Press) or in accordance with the product instruction manual. The reagents or instruments with no specified manufacturer were all conventional products available commercially.
In the examples below, T cells used were from Akeso Biopharma, Inc.; the BALB/C mice were purchased from Guangdong Medical Laboratory Animal Center. The PD-1 HuGEMM mice used were from Nanjing Galaxy Biopharma Co., Ltd.; MC38 cells were from Shanghai Fudan IBS Cell Center; the marketed drug for the same target, Nivolumab (Opdivo®) used was from Bristol-Myers Squibb Company.
Example 1: Acquisition of Hybridoma Cell Line LT003 and Preparation of Monoclonal Antibody 14C12 18 199462198 v1 Used PD1-mFc (PD1: Programmed cell death protein 1, NCBI GenBank ID:NP_005009.2) fusion protein as the antigen, and fused the splenocytes of immunized BALB/C mice (purchased from Guangdong Medical Laboratory Animal Center) and mouse myeloma cells into hybridoma cells by currently established method (for example, Stewart, S.J., "Monoclonal Antibody Production", in Basic Methods in antibody Production and Characterization, Eds.G.C.
Howard and D.R. Bethell, Boca Raton: CRC Press, 2000).
Coating the microplate with PD1-mFc as the antigen, and the hybridoma cells were screened by indirect ELISA to obtain hybridoma cells that secrets new antibodies specifically binding to PD1.
Screened out the hybridoma cell lines capable of secreting monoclonal antibodies binding to PD1 by competition ELISA against the ligand PDL1-hFc fused protein (PDL1: Programmed death-ligand 1, NCBI Genebank ID:NP_054862.1), and obtained stable hybridoma cell lines by limited dilution method, and then obtained stable LT003 cell lines by limited dilution method (the monoclonal antibody secreted from LT003 is named 14C12).
Hybridoma cell line LT003 (PD1-14C12), has been preserved in the China Center for Typical Culture Collection (CCTCC) in Wuhan University, Wuhan, China 430072 on June 16, 2015 with CCTCC Deposit Accession NO: C2015105. 2. Preparation of Monoclonal Antibody 14C12 LT003 cell line in the present invention was cultured using IMDM medium containing 10% low IgG fetal bovine serum for 7 days, and then the cell culture supernatant was harvested and purified to get the antibody 14C12.
Example 2: Acquisition of Light-chain and Heavy-chain Sequences of Monoclonal Antibody 14C12 Extracted mRNA from the hybridoma cell line LT003 prepared in Example 1 above 19 199462198 v1 No DP430).
Synthesized cDNA according to the manual of Invitrogen SuperScript® III First-Strand Synthesis System for RT-PCR Kit and carried out PCR amplification.
Directly carried out TA cloning using the PCR amplification products according to the instructions of pEASY-T1 Cloning Kit (Transgen CT101).
Sequenced the TA cloning products, and obtained the following results: DNA sequencing results of Vh: (354 bp) GAGGTCAAACTGGTGGAGAGCGGCGGCGGGCTGGTGAAGCCCGGCGGGTCAC TGAAACTGAGCTGCGCCGCTTCCGGCTTCGCCTTTAGCTCCTACGACATGTCATGGG TGAGGCAGACCCCTGAGAAGCGCCTGGAATGGGTCGCTACTATCAGCGGAGGCGG GCGATACACCTACTATCCTGACTCTGTCAAAGGGAGATTCACAATTAGTCGGGATA ACGCCAGAAATACTCTGTATCTGCAGATGTCTAGTCTGCGGTCCGAGGATACAGCT CTGTACTATTGTGCAAACCGGTACGGCGAAGCATGGTTTGCCTATTGGGGACAGGG CACCCTGGTGACAGTCTCTGCC ( SEQ ID NO: 1 ) Encoded protein sequence: (118 aa) EVKLVESGGGLVKPGGSLKLSCAASGFAFSSYDMSWVRQTPEKRLEWVATISGG GRYTYYPDSVKGRFTISRDNARNTLYLQMSSLRSEDTALYYCANRYGEAWFAYWGQ GTLVTVSA ( SEQ ID NO: 2 ) DNA sequencing results of Vl: (318 bp) GACATTAAGATGACACAGTCCCCTTCCTCAATGTACGCTAGCCTGGGCGAGCG AGTGACCTTCACATGCAAAGCATCCCAGGACATCAACACATACCTGTCTTGGTTTC AGCAGAAGCCAGGCAAAAGCCCCAAGACCCTGATCTACCGGGCCAATAGACTGGT GGACGGGGTCCCCAGCAGATTCTCCGGATCTGGCAGTGGGCAGGATTACTCCCTGA 199462198 vl GAGTTCCCTCTGACCTTTGGAGCAGGCACAAAACTGGAACTG ( SEQ ID NO: 3 ) Encoded protein sequence: (106 aa) DIKMTQSPSSMYASLGERVTFTCKASQDINTYLSWFQQKPGKSPKTLIYRANRLV DGVPSRFSGSGSGQDYSLTISSLEYEDMGIYYCLQYDEFPLTFGAGTKLEL ( SEQ ID NO: 4 ) 2. Preparation of Recombinant Monoclonal Antibody 14C12 (Re) Separately cloned the heavy-chain cDNA sequence (the variable region sequence is SEQ ID NO:1) and the light-chain cDNA sequence (the variable region sequence is SEQ ID NO:3) of 14C12 (Re) into the pUC57simple (provided by GenScript Biotech Corp.) vector (enzymatic cleavage sites: XbaI & BamHI), and obtained pUC57simple-14C12H and pUC57simple-14C12L plasmids, respectively.
Enzymatically cleaved (HindIII & EcoRI) the plasmids pUC57simple-14C12H and pUC57simple-14C12L, respectively, and then sub-cloned the heavy and light chains recovered from electrophoresis into the pcDNA3.1 vector, extracted both recombinant plasmids and co-transfect 293F cells.
After 7 days cell culture, the cell culture supernatant was centrifuged by high-speed centrifugation and filtered by vacuum filtration with microporous membrane and loaded onto the HiTrap MabSelectSuRe column, and then the antibody was eluted with Elution Buffer in one step, and then went through HiTrap Desalting column, and recovered into PBS buffer,and then the recombinant antibody 14C12 (Re) was obtained after further purification .
As validated by ELISA binding activity assay, the recombinant antibody 14C12 (Re) had a binding activity equivalent to the antibody 14C12, and hence can be further used in the subsequent antibody humanization design. 21 199462198 v1 14C12H1L1 1. Design of Light-chain and Heavy-chain Sequences of Humanized Antibody 14C12H1L1 According to the three-dimensional crystal structure of PD1 protein (Shinohara T, et al., Structure and chromosomal localization of the human PD1 gene (PDCD1). Genomics 1995, 23 (3):704-6)) and the sequences of the antibody 14C12 obtained in Example 2, through computer antibody modeling, amino acids mutation was designed according to the model, and obtained the variable region sequences of the antibody 14C12H1L1 (Heavy chain constant region is Ig gamma-1 chain C region, ACCESSION:P01857; light chain constant region is Ig kappa chain C region, ACCESSION:P01834), as follows: DNA sequence of heavy chain variable region: (354 bp) GAAGTGCAGCTGGTCGAGTCTGGGGGAGGGCTGGTGCAGCCCGGCGGGTCAC TGCGACTGAGCTGCGCAGCTTCCGGATTCGCCTTTAGCTCCTACGACATGTCCTGGG TGCGACAGGCACCAGGAAAGGGACTGGATTGGGTCGCTACTATCTCAGGAGGCGG GAGATACACCTACTATCCTGACAGCGTCAAGGGCCGGTTCACAATCTCTAGAGATA ACAGTAAGAACAATCTGTATCTGCAGATGAACAGCCTGAGGGCTGAGGACACCGC ACTGTACTATTGTGCCAACCGCTACGGGGAAGCATGGTTTGCCTATTGGGGGCAGG GAACCCTGGTGACAGTCTCTAGT ( SEQ ID NO: 5 ) Encoded protein sequence: (118 aa) EVQLVESGGGLVQPGGSLRLSCAASGFAFSSYDMSWVRQAPGKGLDWVATISGG GRYTYYPDSVKGRFTISRDNSKNNLYLQMNSLRAEDTALYYCANRYGEAWFAYWGQ GTLVTVSS ( SEQ ID NO: 6) 22 199462198 v1 GACATTCAGATGACTCAGAGCCCCTCCTCCATGTCCGCCTCTGTGGGCGACAG GGTCACCTTCACATGCCGCGCTAGTCAGGATATCAACACCTACCTGAGCTGGTTTC AGCAGAAGCCAGGGAAAAGCCCCAAGACACTGATCTACCGGGCTAATAGACTGGT GTCTGGAGTCCCAAGTCGGTTCAGTGGCTCAGGGAGCGGACAGGACTACACTCTGA CCATCAGCTCCCTGCAGCCTGAGGACATGGCAACCTACTATTGCCTGCAGTATGAT GAGTTCCCACTGACCTTTGGCGCCGGGACAAAACTGGAGCTGAAG ( SEQ ID NO: 7 ) Encoded protein sequence: (107 aa) DIQMTQSPSSMSASVGDRVTFTCRASQDINTYLSWFQQKPGKSPKTLIYRANRLVS GVPSRFSGSGSGQDYTLTISSLQPEDMATYYCLQYDEFPLTFGAGTKLELK ( SEQ ID NO: 8 ) Example 4: Preparation and SDS-PAGE Electrophoresis of Humanized Monoclonal Antibody 14C12H1L1 Separately cloned the heavy-chain cDNA (the variable region sequence is SEQ ID NO:5, heavy chain constant region is Ig gamma-1 chain C region, ACCESSION:P01857) and light-chain cDNA (the variable region sequence is SEQ ID NO:7, light chain constant region is Ig kappa chain C region, ACCESSION:P01834) of 14C12H1L1 into the pUC57simple (provided by GenScript Biotech Corp.) vector (enzymatic cleavage sites: XbaI & BamHI) to obtain pUC57simple-14C12H1 and pUC57simple-14C12L1 plasmids, respectively.
Sub-cloned thees plasmids into pcDNA3.1 vector respectively (enzymatic cleavage sites: XbaI & BamHI), extracted both recombinant plasmids and co-transfect 293F cells.
After 7 days cell culture, the cell culture was centrifuged by high-speed centrifugation and 23 199462198 v1 MabSelectSuRe column, and then the antibody was eluted with Elution Buffer in one step, went through HiTrap Desalting column and recovered into PBS buffer, and purified further to obtain the recombinant antibody 14C12H1L1, which was analyzed by SDS-PAGE electrophoresis.
The results were shown in Figure 1, the reduced target protein appeared at approximately 24.5 kD and 49 KD, and the non-reduced target protein appeared at approximately 147 kD.
Example 5: Kinetics Measurements of the Antibodies The binding kinetics of the antibody 14C12 and humanized antibody 14C12H1L1 to the antigen PD1 was measured by Fortebio Octet System. 1. Cleaved PD1-mFc protein with TEV protease, and obtained PD1 antigen by column purification. 2. The antigen PD1 (the concentration at 1 |!g/ml) labeled with biotin was immobilized on the surface of SA sensor and equilibrated in PBST buffer, and then bound antibodies 14C12, 14C12H1L1 and 5C4, and the antibodies were diluted with each dilution three-fold relative to the previous one since 200nM. The dissociation of antigen and antibody were also in PBST.
Binding kinetics of the antibodies 14C12, 14C12H1L1 and 5C4 were shown in Table 1 and Figures 2, 3 and 4, respectively. The results showed that both 14C12 and 14C12H1L1 had good affinities to PD1, with a higher affinity than that of 5C4.
Table 1: Dynamic Parameters of Antibody 14C12.
Antibody Name Kd (M) Kon (1/Ms) Ko Error Kdis (1/s) Kdis Error 14C12 1.81E-11 3.38E+05 8.23E+03 6.12E-06 1.04E-05 14C12H1L1 2.42E-11 3.17E+05 5.90E+03 7.66E-06 8.70E-06 5C4 6.46E-10 5.63E+05 1.38E+04 3.63E-04 9.77E-06 Kd: Dissociation constant; 24 199462198 v1 Kdis: Dissociation rate of antigen and antibody; Kd = Kdis/Kon.
Example 6: Binding Activity of Antibody and Antigen PD1 Measured by Indirect ELISA The binding activities of antibodies 14C12H1L1 and 5C4 to PD1 were measured separately by indirect ELISA as follows: After incubated with PD1-mFc at 4°C overnight, the microplate was blocked with 1% BSA at 37°C for 2h, and then the antibodies were added separately and incubated at 37°C for 30 min, and then HRP-labeled secondary antibody (goat anti-human IgG (H+L)) (Jackson, 109-035-088) was added. and then TMB (Neogen, 308177) was added to react for 5 mins and the absorbance was read at the wavelength of 450 nm in a microplate reader.
The binding results of antibodies 14C12H1L1 and 5C4 to the antigen PD1 were shown in Figure 5. As shown in Figure 5, both the antibodies 14C12H1L1 and 5C4 can bind to PD1 protein effectively with dose-dependency. The absorbance intensities at different doses were shown in Table 2. Through Curve Simulation using quantitative analyses of absorbance values, EC50 of 14C12H1L1 and 5C4 binding with PD1 were then determined to be 0.032nM and 0.043 nM, respectively.
Table 2: Absorbance Intensities of 14C12H1L1 and 5C4 binding to PD1 Antigen coating: PD1-mFc (0.5 p,g/mL) Antibody concentration (^g/mL) 14C12H1L1 5C4 1 2.970 2.954 2.959 2.991 0.3 2.886 2.961 2.978 3.079 0.1 2.864 2.868 2.838 2.926 0.03 2.674 2.669 2.617 2.659 0.01 2.222 2.201 1.981 2.221 0.003 1.383 1.464 1.169 1.222 0.001 0.676 0.736 0.527 0.548 199462198 v1 Secondary Antibody HRP-labeled secondary antibody (goat anti-human IgG) Example 7: Binding Activities of Antibodies to Antigen PD1 against PDL1 by competition ELISA Binding activities of humanized antibody 14C12H1L1 and 5C4 to antigen PD1 against PDL1 were measured by competition ELISA as follows: After incubated with PD1-hFc at 4°C overnight, the microplate was blocked with 1% BSA for 2h, and antibodies 14C12H1L1 and 5C4 with different concentrations (see Table 3 for the dilute strengths) were mixd with PDL1-mFc for 10 min, and the mixtures were incubated at 37°C for 30 min, and then corresponding anti-human and anti-mouse enzyme-labeled second antibodies respectively and incubate at 37°C for 30 min were added. The absorbance at the wavelength of 450 nm was read in a microplate reader.
The binding results of antibodies 14C12H1L1 and 5C4 to the antigen PD1 were shown in Figure 6. As shown in Figure 6, the antibody 14C12H1L1 can compete against PDL1 and bind to PD1 protein effectively with dose-dependency. The absorbance intensities at different doses were shown in Table 3. Through Curve Simulation using quantitative analyses of absorbance values, EC50 of 14C12H1L1 and 5C4 binding activity were then determined to be 1.322 nM and 1.199 nM, respectively.
Table 3: Competitive Binding of 14C12H1L1 and 5C4 to PD1 against PDL1 Antigen coating PD1-mFc 0.5gg/mL Antibody concentration/dilution 14C12H1L1 5C4 gradient 1.5gg/ml 0.062 0.064 0.070 0.075 1:3 0.069 0.064 0.081 0.086 1:9 0.363 0.305 0.372 0.269 1:27 1.727 1.543 1.429 1.604 1:81 1.892 1.752 1.766 1.881 1:243 1.984 2.029 2.045 2.005 1:729 1.937 1.978 1.934 1.954 0 1.870 1.977 1.933 1.977 26 199462198 v1 Secondary Antibody HRP-labeled goat anti-mouse secondary antibody Example 8: Binding Activity of Antibodies to Cell Surface Antigen PD1 by Flow Cytometry Host cells 293T expressing PD1 antigen were constructed, and labeled with the humanized antibody 14C12H1L1 prepared in the present invention (see Example 4). The ability of the antibody 14C12H1L1 to bind specifically to cell surface antigen in its native conformation was analyzed and validated by flow cytometry. 1. Construction of Host Cell 293T Expressing PD1 Antigen The specific steps were as follows: Construction of the host cell 293T expressing PD1 antigen: 293T cells were transfected with the PD1-containing vector pLenti6.3-PD1 (vector pLenti6.3 was purchased from Invitrogen Corporation) according to the manual of LipofectaminTransfection Kit (purchased from Invitrogen Corporation) to obtain the stable pool of 293T-PD1 expressing PD1 by screening. 2. Binding of Antibodies to 293T-PD1 Cell Surface Antigen Antibody labeling and flow cytometry: The 293T-PD1 obtained by the step above was digested by trypsin, and distributed into tubes each containing2x105 cells. PD1 antibodies was diluted using PBSbuffer (1% BSA) at concentrations of 50 nM, 10 nM, 5 nM, 1 nM, 0.1 nM and 0.01 nM and added into the tubes and incubated on ice with PD1-expressing 293T cells for2h. 100 ^L of FITC-labeled goat anti-human secondary antibody (1:500) was added into each tube and incubated on ice for 1h. After washed with PBS 3 times, cells were re-suspended in 300 ^L of PBS and fluorescence signals were measured on the flow cytometer using the FITC channel.
The binding results of the humanized antibody 14C12H1L1 to 293T-PD1 cells were shown in Figure 7. As shown in Figure 7, the antibody 14C12H1L1 can bind target PD1 27 199462198 v1 The fluorescence intensities at different doses were shown in Table 4. Through Curve Simulation using quantitative analyses of fluorescence intensities, EC50 of 14C12H1L1 binding with PD1 was then determined to be 1.89 nM.
Table 4: The Fluorescence Intensities of 14C12H1L1 Binding to 293T-PD1 Surface Antigen Detected by Flow Cytometry Concentration (nM) 0.01 0.1 1 5 10 50 Fluorescence Intensity 8.32 20.31 174.62 579.41 686.49 669.54 Example 9: Binding Activity of Antibody to T Cell Surface Antigen PD1 by Flow Cytometry PBMC was isolated by Ficoll-Paque Plus (GE Healthcare LOT No.: 171440-02), further isolated to get CD4+ cells, and cells were stimulated with PHA (Shanghai Shenqi Biotech Co., Ltd, 50 |1l/ml) for three days, and then washed once with PBS, and antibodies at different concentrations were added and incubated on ice for 1.5 h. The cells were then washed with PBS once after incubation, and the FITC-labeled goat anti-human secondary antibody (Jackson immunoresearch lot. 102155) was added and incubated on ice in the dark for 1h, and after washed with PBS once, the fluorescence signals were measured on the flow cytometer.
The binding results of humanized antibody 14C12H1L1 to Tcells were shown in Figure 8.
Evidently, the antibody 14C12H1L1 can bind PD1 protein on T cell surface effectively with dose-dependency.
Example 10: Mixed Lymphocyte Reaction: Secretion of Cytokines IFN-y, IL-2 PBMC was isolated by Ficoll-Paque Plus (GE Healthcare LOT No.: 171440-02), add the isolated PBMC was induced with IL-4 (Peprotech K2513, 1,000 U/ml) and GM-CSF (Peprotech H1513, 1,000 U/ml) for 6 days, and then TNF-a (Peprotech G1513, 200 U/ml) was 28 199462198 v1 T cells were isolated from PBMC and mixed with the DC cells obtained above in the ratio of 10:1 to culture together with the antibodies 14C12H1L1, 5C4 and hIgG (hIgG as an isotype control) in different ratios for 5-6 days. The secretions of IFN-y and IL-2 were measured with corresponding ELISA reagent kits (both purchased from Dakewe) respectively.
The secretions of IFN-y and IL-2 after mixed culture of DC cells and T cells were shown in Figures 9 and Figures 10. 14C12H1L1 antibody can effectively induce the secretions of IFN-y and IL-2 with dose-dependency. Antibody 14C12H1L1 can induce higher secretions of both IFN-y and IL-2 than the control antibody 5C4.
Example 11: Induced IL-2 Secretion The isolated PBMC (the same method as in Example 10) was stimulated with PHA (Shanghai Shenqi Biotech Co., Ltd, 50^l/ml) for 3 days, and then mature PBMC (5*104 cells/well) mixed with Raji cells (Chinese Academy of Sciences Shanghai Branch) (5*104 cells/well) and MDA-MB-231 cells (ATCC) (1*104 cells/well) in a 96-well plate. 100 nM of 14C12H1L1 or control antibody 5C4 or hIgG (hIgG as the isotype control) were added and mixed and cultured together for three days. The secretion of IL-2 was detected with ELISA reagent kit (purchased from Dakewe) according to the instructions of the kit.
The results of IL-2 secretion after mixed cell culture were shown in Figure 11. As shown in Figure 11, antibody can effectively induce PBMC to secret IL-2, and the IL-2 secretion induced by 14C12H1L1 is significantly higher than that of control antibody 5C4.
Example 12: Impact of Antibody 14C12H1L1 on the Tumor Growth of MC38 Tumor Model in PD-1 HuGEMM Mice MC38 tumor cells (1*106 cells/mouse) were inoculated subcutaneously on the right side of PD-1 HuGEMM mice (human PD-1 transgenic mice). When the mean tumor volume 29 199462198 v1 with 8 mice in each group. Antibodies were given through abdominal administration. The specific grouping and dosages were as follows: Isotype Control group (dose: 8 mg/kg), 14C12H1L1 high-dose group (dose: 8 mg/kg), 14C12H1L1 low-dose group (dose: 0.8 mg/kg), Nivolumab group (dose: 8 mg/kg).
The above 4 groups were injected with antibodies twice weekly, 5 doses in total. After injection, the tumor sizes were measured twice weekly.
The results were presented in Figure 12.
The results indicating that: The tumor sizes in the Nivolumab, 14C12H1L1 high-dose, and 14C12H1L1 low-dose groups were all significantly smaller than those in the Isotype control group statistically (P < 0.01, P < 0.01, P < 0.05, respectively). 14C12H1L1 high-dose group (8 mg/kg) showed a statistically significant antitumor effect on the MC38 tumor model in the PD-1 HuGEMM mice, and had an efficacy equivalent to the approved drug for the same target, Nivolumab (8 mg/kg).
Although specific embodiments of the present invention have been described in detail, as will be appreciated by one skilled in the art, these details may incur various modifications and substitutions according to all the teachings we have disclosed. These changes are all covered by the scope of the present invention. The full scope of the present invention is given by the appended claims and any equivalents. 199462198 v1
Claims (18)
1. A monoclonal antibody or antigen-binding fragment thereof, wherein the heavy chain variable region (V ) of the monoclonal antibody comprises H CDR1 comprising the amino acid sequence of SEQ ID NO: 9, CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and CDR3 comprising the amino acid sequence of SEQ ID NO:11; and the light chain variable region (V ) of the monoclonal antibody comprises L CDR1comprising the amino acid sequence of SEQ ID NO: 12, CDR2 comprising the amino acid sequence of SEQ ID NO: 13, and CDR3 comprising the amino acid sequence of SEQ ID NO:14.
2. The monoclonal antibody or antigen-binding fragment of claim 1, wherein the amino acid sequence of the V of the monoclonal antibody is chosen from H SEQ ID NO: 2 and SEQ ID NO: 6; and the amino acid sequence of the V of the monoclonal antibody is chosen from L SEQ ID NO: 4 and SEQ ID NO: 8; optionally wherein the monoclonal antibody comprises a V amino acid H sequence of SEQ ID NO: 2 and a V amino acid sequence of SEQ ID NO: 4; or a V L H amino acid sequence of SEQ ID NO: 6 and a V amino acid sequence of SEQ ID NO: L 8.
3. The monoclonal antibody or antigen-binding fragment of claim 1 or 2, wherein the monoclonal antibody or antigen-binding fragment is a Fab, Fab', F(ab') , Fd, Fv, 2 dAb, single-chain antibody, scFv, humanized antibody, chimeric antibody, or bispecific antibody.
4. The monoclonal antibody or antigen binding fragment of claim 1 or 2, wherein the binding affinity (K ) to PD1 of the monoclonal antibody or antigen-binding D -5 -6 -7 -8 -9 -10 fragment is less than 10 M, preferably 10 M, 10 M, 10 M, 10 M, or 10 M or less; preferably wherein the K is measured by Fortebio molecular interactions D analyzer. 31 264956/2
5. The monoclonal antibody or antigen binding fragment of claim 1 or 2, wherein the monoclonal antibody or antigen-binding fragment contains non-CDR regions from species other than mouse, preferably human.
6. The monoclonal antibody of claim 1 or 2, wherein the monoclonal antibody is produced by the hybridoma cell line LT003 preserved in China Center for Type Culture Collection (CCTCC) with the CCTCC Deposit Accession NO: C2015105.
7. An isolated nucleic acid molecule comprising a nucleotide sequence coding for the monoclonal antibody or antigen binding fragment of any one of claims 1 to 6.
8. An expression construct comprising the isolated nucleic acid molecule of claim 7.
9. An expression cell line comprising the isolated nucleic acid molecule of claim 7 or the expression construct of claim 8.
10. A method of producing the monoclonal antibody or antigen binding fragment of any one of claims 1 to 6, the method comprising growing the cell line of claim 9 under suitable conditions and recovering the monoclonal antibody or antigen binding fragment from the cell culture.
11. Hybridoma cell line LT003, preserved in the China Center for Typical Culture Collection (CCTCC) with the CCTCC Deposit Accession NO: C2015105.
12. A conjugate comprising the monoclonal antibody or antigen binding fragment of any one of claims 1 to 6 and a conjugating partner as a detectable marker; preferably wherein the conjugating partner comprises radioactive isotopes, fluorescein, luminescent material, colorful substances, or enzymes.
13. A reagent kit comprising the monoclonal antibody or antigen binding fragment of any one of claims 1 to 6, or the conjugate of claim 12; preferably wherein the kit comprises a secondary antibody, which specifically recognizes the monoclonal antibody or antigen binding fragment; optionally wherein the secondary antibody comprises a detectable marker, preferably wherein the detectable marker comprises radioactive isotopes, fluorescein, luminescent material, colorful substances, or enzymes. 32 264956/2
14. Methods to produce reagent kits to detect the existence or levels of PD1 in samples using the monoclonal antibody or antigen binding fragment of any one of claims 1 to 6 or the conjugate of claim 12.
15. A pharmaceutical composition comprising the monoclonal antibody or antigen binding fragment of any one of claims 1 to 6 or the conjugate of claim 12; optionally wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier or excipient.
16. The monoclonal antibody or antigen binding fragment of any one of claims 1 to 6 or the conjugate of claim 12, for use in preparations of the following drugs: drugs blocking the binding of PD1 to PD1 ligand, drugs regulating (e.g. Down-regulating) PD1 activity or level, drugs relieving the immunosuppression of PD1, or drugs up-regulating IFN- and/or IL-2 expressions in T lymphocytes; preferably, wherein the PD1 ligand is PDL1 or PDL2.
17. The monoclonal antibody or antigen binding fragment of any one of claims 1 to 6 or the conjugate of claim 12, for use in the prevention and/or treatment of tumors or anemia, or the diagnosis of tumors or anemia; preferably wherein the tumors are melanoma, renal cancer, prostate cancer, bladder cancer, colorectal cancer, gastrointestinal cancer, liver cancer, non-small cell lung cancer, ovarian cancer or leukemia.
18. The monoclonal antibody or antigen binding fragment of any one of claims 1 to 6 or the conjugate of claim 12, with the following purposes: block the binding of PD1 to PD1 ligand; regulate (e.g. down-regulate) PD1 activity or level; relieve the immunosuppression of PD1; or up-regulate IFN- and/or IL-2 expressions in T lymphocytes; preferably, wherein the PD1 ligand is PDL1 or PDL2. 33
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610705763.5A CN106977602B (en) | 2016-08-23 | 2016-08-23 | A kind of anti-PD1 monoclonal antibodies, its medical composition and its use |
| PCT/CN2017/098465 WO2018036472A1 (en) | 2016-08-23 | 2017-08-22 | Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL264956A true IL264956A (en) | 2022-12-01 |
| IL264956B2 IL264956B2 (en) | 2023-04-01 |
Family
ID=59340342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL264956A IL264956B2 (en) | 2016-08-23 | 2019-02-21 | Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US12076398B2 (en) |
| EP (2) | EP3505535B1 (en) |
| JP (1) | JP7082620B2 (en) |
| KR (1) | KR102469286B1 (en) |
| CN (1) | CN106977602B (en) |
| AU (2) | AU2017316255C1 (en) |
| BR (1) | BR112019003775A2 (en) |
| CA (1) | CA3034849A1 (en) |
| EA (1) | EA201990570A1 (en) |
| ES (1) | ES3001154T3 (en) |
| FI (1) | FI3505535T3 (en) |
| IL (1) | IL264956B2 (en) |
| LT (1) | LT3505535T (en) |
| MX (1) | MX2019002268A (en) |
| NZ (1) | NZ751902A (en) |
| PT (1) | PT3505535T (en) |
| RS (1) | RS66372B1 (en) |
| SG (1) | SG11201901584UA (en) |
| WO (1) | WO2018036472A1 (en) |
| ZA (1) | ZA201901781B (en) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114702586A (en) | 2015-03-13 | 2022-07-05 | 西托姆克斯治疗公司 | anti-PDL 1 antibodies, activatable anti-PDL 1 antibodies, and methods of use thereof |
| CA2991976A1 (en) | 2015-07-13 | 2017-01-19 | Cytomx Therapeutics, Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
| BR112018008867A8 (en) | 2015-11-03 | 2019-02-26 | Janssen Biotech Inc | antibodies that specifically bind to pd-1 and their uses |
| CN106977602B (en) * | 2016-08-23 | 2018-09-25 | 中山康方生物医药有限公司 | A kind of anti-PD1 monoclonal antibodies, its medical composition and its use |
| CN106967172B (en) | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | The anti-PD-1 bifunctional antibody of anti-CTLA 4-, its medical composition and its use |
| WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
| WO2018222949A1 (en) | 2017-06-01 | 2018-12-06 | Cytomx Therapeutics, Inc. | Activatable anti-pdl1 antibodies, and methods of use thereof |
| CN109425736B (en) * | 2017-08-25 | 2021-04-09 | 北京百普赛斯生物科技股份有限公司 | Method and kit for detecting blood concentration of PD-1antibody |
| RU2020113600A (en) * | 2017-09-20 | 2021-10-20 | Ридженерон Фармасьютикалз, Инк. | METHODS FOR IMMUNOTHERAPY OF PATIENTS WHICH TUMORS ARE CHARACTERIZED BY HIGH LOAD OF PASSENGER GENE MUTATIONS |
| TWI841554B (en) | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate |
| EP3773916A4 (en) * | 2018-04-04 | 2021-12-15 | TrueBinding, Inc. | Methods and compositions for blocking interaction between non-glycosylated pd-1 polypeptides |
| JP7519907B2 (en) | 2018-05-07 | 2024-07-22 | ジェンマブ エー／エス | Methods for treating cancer using a combination of anti-PD-1 antibody and anti-tissue factor antibody-drug conjugate |
| KR20210034613A (en) * | 2018-07-18 | 2021-03-30 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | Drug combinations of quinoline derivatives and antibodies |
| CN109053889B (en) * | 2018-07-25 | 2019-06-21 | 博奥信生物技术（南京）有限公司 | A kind of anti-human PD1 monoclonal antibody and purposes |
| CN109053895B (en) | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | Bifunctional antibody for resisting PD-1-VEGFA, pharmaceutical composition and application thereof |
| JP2022527345A (en) | 2019-04-03 | 2022-06-01 | オレガ・バイオテック | Combined therapy based on PD1 and IL-17B inhibitors |
| CN110373415B (en) * | 2019-06-12 | 2023-06-09 | 安徽省昂普拓迈生物科技有限责任公司 | Aptamer specifically binding to PD-L1 protein and application thereof |
| TW202434297A (en) | 2019-07-05 | 2024-09-01 | 日商小野藥品工業股份有限公司 | Treatment of hematological cancer with pd-1/cd3 bispecific protein |
| US20220267444A1 (en) * | 2019-08-02 | 2022-08-25 | CTTQ-Akeso (ShangHai) Biomed. Tech. Co., Ltd. | Anti-pd-1 antibody and medical use thereof |
| US20220332825A1 (en) | 2019-08-08 | 2022-10-20 | Ono Pharmaceutical Co., Ltd. | Bispecific protein |
| CN110903391B (en) * | 2019-10-25 | 2021-05-28 | 东大生物技术(苏州)有限公司 | Group of PD-L1 monoclonal antibodies and medical application thereof |
| CN113004408B (en) * | 2019-12-20 | 2022-07-01 | 广东菲鹏制药股份有限公司 | Anti-human apoptosis factor-1 monoclonal antibody |
| JP2023514957A (en) | 2020-02-28 | 2023-04-12 | オレガ・バイオテック | Combination therapy based on CTLA4 inhibitors and IL-17B inhibitors |
| CA3176321A1 (en) * | 2020-04-22 | 2021-10-28 | Peng Zhang | Anti-cd73-anti-pd-1 bispecific antibody and use thereof |
| WO2021218895A1 (en) | 2020-04-29 | 2021-11-04 | 正大天晴药业集团股份有限公司 | BIFUNCTIONAL PROTEIN AGAINST PD-1 AND TGF-β |
| CN113754767A (en) * | 2020-06-03 | 2021-12-07 | 上海恒润达生生物科技股份有限公司 | Anti-human PD-1 antibodies and uses thereof |
| WO2022068891A1 (en) * | 2020-09-30 | 2022-04-07 | 苏州沙砾生物科技有限公司 | Pd-1 antibody, and preparation method therefor and application thereof |
| JP2023549581A (en) | 2020-11-17 | 2023-11-27 | シージェン インコーポレイテッド | Method of treating cancer with a combination of tucatinib and anti-PD-1/anti-PD-L1 antibodies |
| CN113336848B (en) * | 2021-02-03 | 2022-08-19 | 上海莱馥医疗科技有限公司 | anti-PD-1 antibody and application thereof |
| MX2024000674A (en) | 2021-07-13 | 2024-02-07 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer. |
| KR20240083095A (en) | 2021-09-29 | 2024-06-11 | 아케소 바이오파마, 인크. | Anti-LAG3 antibodies, pharmaceutical compositions and uses |
| JP2024536383A (en) | 2021-10-06 | 2024-10-04 | ジェンマブ エー／エス | Multispecific binding agents to PD-L1 and CD137 in combination |
| WO2023083439A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
| CN113912710B (en) * | 2021-11-17 | 2023-05-26 | 杭州旭科生物技术有限公司 | Monoclonal antibody for resisting novel coronavirus N protein and application thereof |
| CN114316053B (en) * | 2021-12-20 | 2023-09-29 | 南京诺唯赞检测技术有限公司 | VCE monoclonal antibody and preparation method thereof |
| EP4257609A1 (en) | 2022-04-08 | 2023-10-11 | iOmx Therapeutics AG | Combination therapies based on pd-1 inhibitors and sik3 inhibitors |
| CN119031933A (en) * | 2022-04-12 | 2024-11-26 | 正大天晴(广州)医药有限公司 | Combination of proteasome inhibitors and anti-PD-1 antibodies |
| EP4522657A1 (en) | 2022-05-12 | 2025-03-19 | Genmab A/S | Binding agents capable of binding to cd27 in combination therapy |
| EP4522654A1 (en) * | 2022-05-12 | 2025-03-19 | BioNTech SE | Monoclonal antibodies directed against programmed death-1 protein and their use in medicine |
| TW202346342A (en) | 2022-05-13 | 2023-12-01 | 大陸商正大天晴藥業集團南京順欣製藥有限公司 | Drug combination of anti-TIM-3 antibody and anti-PD-1 antibody |
| WO2024051670A1 (en) * | 2022-09-06 | 2024-03-14 | 正大天晴药业集团股份有限公司 | Pharmaceutical combination of antibody binding to tim-3 and antibody binding to pd-1 |
| WO2024077069A1 (en) * | 2022-10-05 | 2024-04-11 | Chulalongkorn University | Monoclonal antibodies against human programmed cell death protein 1 (pd-1) |
| CN117986356A (en) * | 2022-10-27 | 2024-05-07 | 纽迈生物科技(苏州)有限公司 | A method for preparing an antibody |
| WO2024115725A1 (en) | 2022-12-01 | 2024-06-06 | BioNTech SE | Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy |
| WO2024209072A1 (en) | 2023-04-06 | 2024-10-10 | Genmab A/S | Multispecific binding agents against pd-l1 and cd137 for treating cancer |
| CN118652343A (en) * | 2024-07-08 | 2024-09-17 | 北京昌盛鸿途生物科技有限公司 | A clinical blood immune cell and its application in treating diseases |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105175544A (en) * | 2015-10-20 | 2015-12-23 | 安徽瀚海博兴生物技术有限公司 | Anti-PD-1 humanized monoclonal antibody and application thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| PT1537878E (en) | 2002-07-03 | 2010-11-18 | Ono Pharmaceutical Co | Immunopotentiating compositions |
| AU2003288675B2 (en) * | 2002-12-23 | 2010-07-22 | Medimmune Limited | Antibodies against PD-1 and uses therefor |
| US8008449B2 (en) | 2005-05-09 | 2011-08-30 | Medarex, Inc. | Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| SG190572A1 (en) | 2008-04-29 | 2013-06-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| CA2738252C (en) * | 2008-09-26 | 2018-05-01 | Dana-Farber Cancer Institute, Inc. | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| US8642557B2 (en) | 2010-03-12 | 2014-02-04 | Abbvie Biotherapeutics Inc. | CTLA4 proteins and their uses |
| GB201103955D0 (en) | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| CN103429264A (en) * | 2011-03-31 | 2013-12-04 | 默沙东公司 | Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments |
| EP2699264B1 (en) * | 2011-04-20 | 2018-03-14 | Medlmmune, LLC | Antibodies and other molecules that bind b7-h1 and pd-1 |
| WO2014022758A1 (en) | 2012-08-03 | 2014-02-06 | Dana-Farber Cancer Institute, Inc. | Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use |
| WO2014209804A1 (en) | 2013-06-24 | 2014-12-31 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| CN104250302B (en) * | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | The anti-antibody of PD 1 and its application |
| AR097791A1 (en) | 2013-09-27 | 2016-04-13 | Genentech Inc | ANTI-PDL1 ANTIBODY FORMULATIONS |
| SG11201604738TA (en) * | 2013-12-12 | 2016-07-28 | Shanghai Hengrui Pharm Co Ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| CA2930154A1 (en) | 2014-01-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Covalently linked helicar-anti-helicar antibody conjugates and uses thereof |
| TWI681969B (en) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | Human antibodies to pd-1 |
| CN104974253A (en) | 2014-04-01 | 2015-10-14 | 上海中信国健药业股份有限公司 | Anti-CTLA-4/PD-1 bispecific antibody as well as preparation method and application thereof |
| CN105296433B (en) | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | A kind of CTLA4 antibody, its medical composition and its use |
| CN104987421A (en) | 2015-05-13 | 2015-10-21 | 北京比洋生物技术有限公司 | Anti-CTLA-4 and PD-1 dual variable domain immunoglobulin |
| CN105175545B (en) * | 2015-10-20 | 2019-01-25 | 安徽瀚海博兴生物技术有限公司 | An anti-VEGF-anti-PD-1 bifunctional antibody and its application |
| WO2017106061A1 (en) | 2015-12-14 | 2017-06-22 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof |
| CN105754990A (en) | 2016-01-29 | 2016-07-13 | 深圳精准医疗科技有限公司 | Preparation method and application of PD-1/CTLA-4 (programmed death-1/cytotoxic T lymphocyte antigen-4) bispecific antibody |
| WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
| CN106977602B (en) | 2016-08-23 | 2018-09-25 | 中山康方生物医药有限公司 | A kind of anti-PD1 monoclonal antibodies, its medical composition and its use |
| CN106967172B (en) | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | The anti-PD-1 bifunctional antibody of anti-CTLA 4-, its medical composition and its use |
-
2016
- 2016-08-23 CN CN201610705763.5A patent/CN106977602B/en active Active
-
2017
- 2017-08-22 RS RS20250001A patent/RS66372B1/en unknown
- 2017-08-22 AU AU2017316255A patent/AU2017316255C1/en active Active
- 2017-08-22 EP EP17842895.9A patent/EP3505535B1/en active Active
- 2017-08-22 PT PT178428959T patent/PT3505535T/en unknown
- 2017-08-22 EA EA201990570A patent/EA201990570A1/en unknown
- 2017-08-22 JP JP2019531512A patent/JP7082620B2/en active Active
- 2017-08-22 US US16/327,083 patent/US12076398B2/en active Active
- 2017-08-22 FI FIEP17842895.9T patent/FI3505535T3/en active
- 2017-08-22 NZ NZ751902A patent/NZ751902A/en unknown
- 2017-08-22 MX MX2019002268A patent/MX2019002268A/en unknown
- 2017-08-22 BR BR112019003775A patent/BR112019003775A2/en unknown
- 2017-08-22 KR KR1020197008464A patent/KR102469286B1/en active Active
- 2017-08-22 EP EP24206755.1A patent/EP4509186A2/en active Pending
- 2017-08-22 CA CA3034849A patent/CA3034849A1/en active Pending
- 2017-08-22 SG SG11201901584UA patent/SG11201901584UA/en unknown
- 2017-08-22 ES ES17842895T patent/ES3001154T3/en active Active
- 2017-08-22 LT LTEPPCT/CN2017/098465T patent/LT3505535T/en unknown
- 2017-08-22 WO PCT/CN2017/098465 patent/WO2018036472A1/en unknown
-
2019
- 2019-02-21 IL IL264956A patent/IL264956B2/en unknown
- 2019-03-22 ZA ZA2019/01781A patent/ZA201901781B/en unknown
-
2024
- 2024-04-17 AU AU2024202527A patent/AU2024202527A1/en active Pending
- 2024-07-22 US US18/780,086 patent/US20250041409A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105175544A (en) * | 2015-10-20 | 2015-12-23 | 安徽瀚海博兴生物技术有限公司 | Anti-PD-1 humanized monoclonal antibody and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| ANONYMOUS, STUDY OF REGN2810 (ANTI-PD-1) IN PATIENTS WITH ADVANCED MALIGNANCIES - FULL TEXT VIEW - CLINICALTRIALS.GOV, 9 March 2015 (2015-03-09) * |
| BRAHMER ET AL.,, NIVOLUMAB: TARGETING PD-1 TO BOLSTER ANTITUMOR IMMUNITY,, 1 May 2015 (2015-05-01) * |
| MCDERMOTT ET AL.,, PEMBROLIZUMAB: PD-1 INHIBITION AS A THERAPEUTIC STRATEGY IN CANCER,, 1 January 2015 (2015-01-01) * |
Also Published As
| Publication number | Publication date |
|---|---|
| FI3505535T3 (en) | 2025-01-09 |
| WO2018036472A1 (en) | 2018-03-01 |
| PT3505535T (en) | 2025-01-13 |
| EP3505535A1 (en) | 2019-07-03 |
| CN106977602B (en) | 2018-09-25 |
| BR112019003775A2 (en) | 2019-06-25 |
| AU2017316255A1 (en) | 2019-04-11 |
| AU2024202527A1 (en) | 2024-05-16 |
| JP2019534034A (en) | 2019-11-28 |
| SG11201901584UA (en) | 2019-03-28 |
| KR20190050994A (en) | 2019-05-14 |
| ES3001154T3 (en) | 2025-03-04 |
| IL264956B2 (en) | 2023-04-01 |
| JP7082620B2 (en) | 2022-06-08 |
| CN106977602A (en) | 2017-07-25 |
| LT3505535T (en) | 2025-01-27 |
| CA3034849A1 (en) | 2018-03-01 |
| AU2017316255C1 (en) | 2024-08-22 |
| EA201990570A1 (en) | 2019-08-30 |
| EP3505535A4 (en) | 2020-04-15 |
| US20250041409A1 (en) | 2025-02-06 |
| EP3505535B1 (en) | 2024-10-16 |
| KR102469286B1 (en) | 2022-11-22 |
| US12076398B2 (en) | 2024-09-03 |
| RS66372B1 (en) | 2025-02-28 |
| MX2019002268A (en) | 2019-10-21 |
| EP4509186A2 (en) | 2025-02-19 |
| US20190321466A1 (en) | 2019-10-24 |
| NZ751902A (en) | 2022-05-27 |
| ZA201901781B (en) | 2023-10-25 |
| AU2017316255B2 (en) | 2024-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250041409A1 (en) | Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof | |
| US20240010728A1 (en) | Anti-ctla4 and anti-pd-1 bifunctional antibody, pharmaceutical composition thereof and use thereof | |
| EP3882275A1 (en) | Anti-pd-1 and anti-vegfa bifunctional antibody, pharmaceutical composition thereof and use thereof | |
| KR20190117493A (en) | Anti PD-1 Antibodies and Uses thereof | |
| KR20230166096A (en) | CLDN18.2 antigen binding protein and its applications | |
| CN114478769A (en) | anti-TIGIT antibody, and pharmaceutical composition and use thereof | |
| KR20240038043A (en) | Pharmaceutical compositions and uses | |
| AU2021363350A1 (en) | Anti-cd73 antibody and use thereof | |
| KR20250035543A (en) | Bispecific antibodies comprising anti-CLDN18.2 antibodies and pharmaceutical compositions thereof and uses thereof | |
| EA042479B1 (en) | MONOCLONAL ANTIBODY AGAINST PD1, ITS PHARMACEUTICAL COMPOSITION AND THEIR USE | |
| EA042365B1 (en) | BIFUNCTIONAL ANTIBODY AGAINST CTLA4 AND AGAINST PD-1, ITS PHARMACEUTICAL COMPOSITION AND THEIR APPLICATION | |
| NZ791623A (en) | Anti-CTLA4 and anti-PD-1 bifunctional antibody, pharmaceutical composition thereof and use thereof | |
| NZ791621A (en) | Anti-CTLA4 and anti-PD-1 bifunctional antibody, pharmaceutical composition thereof and use thereof |